AP NEWS

Generex Announces Appointment of Marshal Schictman, Esq. as Executive Vice President General Counsel and Corporate SEC Attorney

February 12, 2019

- Veteran Securities Attorney Joins Management to Guide M&A Initiatives, SEC Regulatory Affairs, and Generex Up-listing

MIRAMAR, FL, Feb. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (OTCQB: GNBT) is pleased to announce that Marshal Schictman, Esq. has joined the executive management team as Executive Vice President, General Counsel to oversee the company’s M&A activities, regulatory affairs and SEC filings. Mr. Schictman has practiced law for over 16 years, with wide-ranging expertise in the areas of corporate, securities, and finance law, primarily in the areas of capital markets and securities trading. He has acted as general counsel for public and private companies, performing litigations and corporate transactional work, both domestically and internationally.

Mr. Schictman brings a wealth of experience in capital markets, serving as outside general securities counsel for several public companies, handling securities filings, capital transactions, financing, administrative hearings and inquiries, contested proxies, and Board and annual meetings.

Mr. Schictman attained his undergraduate degree from Boston University, his law degree from Touro Law Center, his MBA in Finance from Long Island University, his LLM in International Taxation and Offshore Financial Centers from St. Thomas University, and studied for passing the bar at Oxford-Brookes University in the United Kingdom. He is licensed to practice in the State of New York, 2nd Circuit Court of Appeals for the State of New York, the Eastern and Southern Federal Districts for the State of New York, and he maintains a current practicing certificate in England and Wales.

“I have worked with Marshal for several years, and he has earned his reputation as an expert in SEC regulations and public company fiduciary matters,” said Joseph Moscato, CEO of Generex. “I am very proud to have such a high caliber executive join our outstanding management team as we execute on our strategic plan to the benefit of our shareholders.”

Mr. Schictman provided his thoughts on joining the Generex executive management team, “I am excited and honored that Joe has asked me to be part of the exciting future of Generex. I look forward to advancing the company’s strategy as an integrated healthcare holding company as we build corporate value through strategic acquisitions and operational excellence.”

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immuno-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact: Generex Biotechnology Corporation Joseph Moscato 646-599-6222 Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

AP RADIO
Update hourly